192 related articles for article (PubMed ID: 31444368)
1. A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma.
Jan YH; Lai TC; Yang CJ; Huang MS; Hsiao M
Sci Rep; 2019 Aug; 9(1):12329. PubMed ID: 31444368
[TBL] [Abstract][Full Text] [Related]
2. Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1α to drive lung adenocarcinoma metastasis.
Jan YH; Lai TC; Yang CJ; Lin YF; Huang MS; Hsiao M
J Hematol Oncol; 2019 Jan; 12(1):12. PubMed ID: 30696468
[TBL] [Abstract][Full Text] [Related]
3. Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3.
Jan YH; Tsai HY; Yang CJ; Huang MS; Yang YF; Lai TC; Lee CH; Jeng YM; Huang CY; Su JL; Chuang YJ; Hsiao M
Cancer Res; 2012 Oct; 72(19):5119-29. PubMed ID: 23002211
[TBL] [Abstract][Full Text] [Related]
4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
5. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
6. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic potential of Adenylate kinase 2 in lung adenocarcinoma.
Liu H; Pu Y; Amina Q; Wang Q; Zhang M; Song J; Guo J; Mardan M
Sci Rep; 2019 Nov; 9(1):17757. PubMed ID: 31780678
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.
Zhang L; Zhang Z; Yu Z
J Transl Med; 2019 Dec; 17(1):423. PubMed ID: 31847905
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Wu CH; Hwang MJ
Cancer Med; 2019 Oct; 8(13):5850-5861. PubMed ID: 31407494
[TBL] [Abstract][Full Text] [Related]
10. Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion.
Xin F; Yao DW; Fan L; Liu JH; Liu XD
Clin Exp Med; 2019 Nov; 19(4):525-534. PubMed ID: 31463832
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel adenylate kinase system in the brain: cloning of the fourth adenylate kinase.
Yoneda T; Sato M; Maeda M; Takagi H
Brain Res Mol Brain Res; 1998 Nov; 62(2):187-95. PubMed ID: 9813319
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma.
Mao Y; Xu R
Biomed Pharmacother; 2020 Mar; 123():109771. PubMed ID: 31881486
[TBL] [Abstract][Full Text] [Related]
15. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
Wang L; Meng Y; Zhang QY
BMC Cancer; 2019 Apr; 19(1):293. PubMed ID: 30940109
[TBL] [Abstract][Full Text] [Related]
16. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with Lung Adenocarcinoma.
Liu K; Kang M; Liao X; Wang R
PLoS One; 2019; 14(7):e0219467. PubMed ID: 31323040
[TBL] [Abstract][Full Text] [Related]
19. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
20. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
